论文部分内容阅读
目的:探究孟鲁司特治疗小儿毛细支气管炎的疗效及预防喘息反复发作的临床价值。方法:选取2012年4月-2014年12月本院确诊的96例毛细支气管炎患儿为研究资料,将其分为对照组和观察组,每组48例。对照组患儿给予常规治疗,观察组在常规治疗基础上增加孟鲁司特口服。随访12个月后,对两组患儿的治疗有效率、症状消失时间以及病情复发情况进行对比分析。结果:观察组患儿的治疗总有效率为93.75%,优于对照组的75%,组间比较,差异具有统计学意义(P<0.05);观察组患儿咳嗽、喘息及肺部症状消失时间以及病情复发情况均优于对照组,差异具有统计学意义(P<0.05)。结论:孟鲁司特治疗毛细支气管炎的临床效果较好,且对喘息反复发作具有预防作用。
Objective: To investigate the clinical efficacy of montelukast in the treatment of children with bronchiolitis and to prevent recurrent wheezing. Methods: A total of 96 children with bronchiolitis diagnosed in our hospital from April 2012 to December 2014 were selected as study data and divided into control group and observation group, 48 cases in each group. The control group of children given conventional treatment, the observation group on the basis of conventional therapy to increase montelukast oral. After 12 months of follow-up, the treatment efficiency, the disappearance of symptoms and the relapse of the two groups were compared. Results: The total effective rate of treatment group was 93.75%, which was better than that of the control group (75%). The differences between the two groups were statistically significant (P <0.05). The cough, wheezing and pulmonary symptoms disappeared in the observation group Time and disease recurrence were better than the control group, the difference was statistically significant (P <0.05). CONCLUSION: Montelukast has a good clinical effect in treating bronchiolitis and has a preventive effect on recurrent wheezing.